Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments.

Date publication

avril 2019

Journal

Journal of acquired immune deficiency syndromes (1999)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROHR Olivier

Tous les auteurs :
Kula A, Delacourt N, Bouchat S, Darcis G, Avettand-Fenoel V, Verdikt R, Corazza F, Necsoi C, Vanhulle C, Bendoumou M, Burny A, De Wit S, Rouzioux C, Rohr O, Van Lint C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30768485

Résumé

Few single latency-reversing agents (LRAs) have been tested in vivo, and only some of them have demonstrated an effect, albeit weak, on the decrease of latent reservoir. Therefore, other LRAs and combinations of LRAs need to be assessed. Here, we evaluated the potential of combined treatments of therapeutically promising LRAs, disulfiram and romidepsin.

Mots clés

Anti-HIV Agents, administration & dosage, Cell Line, Depsipeptides, administration & dosage, Disulfiram, administration & dosage, Drug Therapy, Combination, HIV Infections, drug therapy, HIV-1, drug effects, Humans, Virus Activation, drug effects, Virus Latency, drug effects

Référence

J. Acquir. Immune Defic. Syndr.. 2019 04 15;80(5):605-613